Loading...
Market
New mRNA technology partnerships formed post-patent ruling
5
Resolution / Starting Odds
Moderna forms new partnerships • 25%
Pfizer/BioNTech forms new partnerships • 25%
Both companies form new partnerships • 25%
No new partnerships formed • 25%
Press releases and official company announcements
Story
Moderna Wins European Patent Dispute Against Pfizer, BioNTech Over COVID-19 Vaccine in Legal Battle
May 17, 2024, 10:30 PM
Moderna has emerged victorious in a European patent dispute against Pfizer and BioNTech over its COVID-19 vaccine. The European Patent Office upheld Moderna's key patent, marking a significant win in the ongoing legal battle with its rivals.
View original story
Similar markets
Partnership with Pfizer • 25%
Partnership with Johnson & Johnson • 25%
Partnership with Merck • 25%
No new partnership • 25%
None • 25%
1-2 partnerships • 25%
3-4 partnerships • 25%
More than 4 • 25%
None • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
No new partnerships • 33%
Partner with a major pharmaceutical company • 33%
Partner with multiple smaller pharmaceutical companies • 33%
Pfizer • 20%
Moderna • 20%
Gilead Sciences • 20%
Biogen • 20%
No major announcements • 20%
Moderna performs best • 33%
Pfizer performs best • 33%
BioNTech performs best • 33%
1-2 partnerships • 33%
3-5 partnerships • 33%
More than 5 partnerships • 34%
0 partnerships • 25%
1-2 partnerships • 25%
3-5 partnerships • 25%
More than 5 partnerships • 25%
Moderna most trusted • 33%
Pfizer most trusted • 33%
BioNTech most trusted • 33%
Pharmaceutical Company • 25%
Biotechnology Firm • 25%
Academic Institution • 25%
No new partnership • 25%
